Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer

ONCOLOGY

Volumn 11, Issue 4, 1997, Pages 475-485

  Deantoni, Edward P ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGE; AGED; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; REFERENCE VALUE; REVIEW;

ADULT; AGE FACTORS; AGED; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 0031112744     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991.
2. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: Update 1994. J Urol 152:1358-1368, 1994.
3. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985.
4. Cohen P, Peehl DM, Lamson G, et al: Insulin-like growth factors (IGFs), IGF receptors, and IGF binding proteins in primary cultures of prostate epitheiial cells. J Clin Endocrinol Metab 73:401-407, 1991.
5. Cohen P, Graves HCB, Peehl DM, et al: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75:1046-1053, 1992.
6. Christensson A, Laurell C-B, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755-763, 1990.
7. Wang MC, Valenzuela LA, Murphy GP, et al: Purification of human prostate-specific antigen. Invest Urol 17:159-163, 1979.
8. Qui S-D, Young CY, Bilhartz DL, et al: In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144:1550-1556, 1990.
9. Schmid H-P, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. Cancer 71:2031-2040, 1993.
10. !0. Stamey TA, Yang N, Hay AR, et al: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987.
11. Smith DS, Catalona WJ: Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45:70-75, 1995.
12. Littrup PJ, Kane RA, Mettlin CJ, et al: Cost-effective prostate cancer detection: Reduction of low-yield biopsies: The investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 74:3077-3079, 1994.
13. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991.
14. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841-845, 1992.
15. Labrie F, Dupont A, Suburu R, et al: Serum prostate specific antigen: A prescreening test for prostate cancer. J Urol 147:846-852, 1992.
16. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J Urol 151:1283-1290, 1994.
17. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011-1017, 1989.
18. Richie JP, Catalona WJ, Ahmann FR, et al: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 42:365-374, 1993.
19. Begg CB: Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer. Semin Oncol 21:569-579, 1994.
20. Benson MC, Whang IS, Olsson CA, et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen J Urol 147:817-821, 1992.
21. Kalish J, Cooner WH, Graham Jr SD: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43:601-606, 1994
22. Carter HB, Pearson JD: PSA velocity for the diagnosis of early prostate cancer: A new concept. Urol Clin North Am 20:665-670, 1993.
23. Lilja H: Significance of different molecular forms of serum PSA: The free, noncomplexed form of PSA versus that complexed to al-antichymotrypsin. Urol Clin North Am 20:681-686, 1993.
24. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214-1220, 1995
25. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860-864, 1993.
26. Seaman E, Whang M, Olsson CA, et al: PSA density (PSAD): Role in patient evaluation and management. Urol Clin North Am 20:653-663, 1993.
27. Jewett MAS, Jain U, Toi A, et al: Prostate specific antigen density (PSAD): Can it distinguish between benign hyperplasia and malignancy (abstract)? J Urol 149:415A, 1993.
28. Brawer MK, Aramburu FAG, Chen GL, et al: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150:369-373, 1993.
29. Babaian RJ, Kojima M, Ramierez EI, et al: Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer J Urol 156:432-437, 1996.
30. Collins GN, Lee RJ, McKelvic GB, et al: Relationship between prostate specific antigen, prostate volume, and age in the benign prostate. Br J Urol 71:445-450, 1993.
31. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992.
32. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed, and total serum prostate specific antigen: The establishment of appropriate reference ranges for the concentrations and ratios. J Urol 154:1090-1095, 1995.
33. Babaian RJ, Miyashita H, Evans RB, et al: The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: Relationship to gland volume and age. J Urol 147:837-840, 1992.
34. Oesterling JE: The importance of patient age and race in establishing appropriate reference ranges for serum PSA. Proceedings from the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Paris, France, June 22-24, 1994.
35. Oesterling JE: Using prostate-specific antigen to eliminate unnecessary diagnostic tests: Significant worldwide economic implications. Urology 46(suppl 3A):26-33, 1995.
36. Dalkin BL, Ahmann FR, Kopp JB Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150:1837-1839, 1993.
37. DeAntoni EP, Crawford ED, Oesterling JE, et al: Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 48:234-239, 1996
38. Oesterling JE, Jacobsen SJ, Cooner WH: The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 153:1160-1163, 1995.
39. Partin AW, Criley SR, Subong ENP, et al: Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 155:1336-1339, 1996
40. El-Galley RES, Petros JA, Saunders WH, et al: Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 46:200-204, 1995.
41. Lankford SP, Peters KL, Elser RC: Potential effects of age-specific reference ranges for serum prostate-specific antigen. Eur Urol 27:182-186, 1995.
42. Reissigl A, Pointer J, Horninger W, et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: Results of a large screening study. Urology 46:662-665, 1995.
43. Bangma CH, Kranze R, Blijenberg BG, et al: The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 46:779-784, 1995.
44. Speights Jr VO, Brawn PN, Foster DM, et al: Evaluation of age-specific normal ranges for prostate-specific antigen. Urology 45:454-458, 1995.
45. Mettlin C, Littrup PJ, Kane RA, et al: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 74:1615-1620, 1994.
46. Weichert-Jacobsen K, Tilmann L: Clinical significance of prostate specific antigen age-specific reference ranges. J Urol 153:465A, 1995 Abstract.
47. Borer JG, Sherman J, Solomon MC, et al: Age-specific reference ranges for prostate specific antigen and digital rectal examination may not safely eliminate further diagnostic procedures. J Urol 155:322A, 1996, Abstract.
48. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2037-2042, 1994.
49. Catalona WJ, Smith DS: Comparison of different serum prostate specific antigen measures for early prostate cancer detection (editorial). Cancer 74:1516-1518, 1994.
50. Catalona WJ: What to do when the PSA is 'abnormal.' Proceedings from the American Urological Association Meeting, Orlando, Florida. May 6, 1996.
51. Fleming C, Barry MJ, Oesterling JE: Prostate-specific antigen (PSA) age-specific reference ranges versus a single threshold: Is the best answer to bypass PSA and biopsy everyone (abstract)? J Urol 155:452A, 1996.
52. Petteway J, Brawer MK: Age specific vs 4.0 ng/mL as a PSA cutoff in the screening population: Impact on cancer detection (abstract) J Urol 153:465A, 1995.
53. Myrtle JF, Klimley PG, Ivor LP, et al: Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer, in Advances in Cancer Diagnostics. San Diego, Hybritech, Inc., 1986.
54. Meshref AW, Bazinet M, Trudel C, et al: Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology 45:972-979, 1995.
55. Pearson JD, Carter HB, Metter EJ, et al. Sensitivity and specificity of age-specific reference ranges for PSA velocity (abstract). J Urol 153:465A, 1995.
56. Anderson JR, Strickland D, Corbin D, et al: Age-specific reference ranges for serum prostate-specific antigen. Urology 46:54-57, 1995.
57. Nadler RB, Humphrey PA, Smith DS, et al: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407-413, 1995.